4.99
0.20%
+0.04
전일 마감가:
$4.95
열려 있는:
$4.99
하루 거래량:
87,628
시가총액:
$254.45M
수익:
$100.39M
순이익/손실:
$-217.57M
주가수익비율:
-1.2082
EPS:
-4.13
순현금흐름:
$-180.72M
1주 성능:
+8.77%
1개월 성능:
+0.81%
6개월 성능:
+95.28%
1년 성능:
-56.61%
2seventy bio Inc Stock (TSVT) Company Profile
명칭
2seventy bio Inc
전화
339-499-9300
주소
60 Binney Street, Cambridge
2seventy bio Inc Stock (TSVT) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-09-13 | 다운그레이드 | Goldman | Buy → Neutral |
2023-09-12 | 다운그레이드 | Guggenheim | Buy → Neutral |
2023-07-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2022-10-31 | 개시 | Guggenheim | Buy |
2022-05-02 | 개시 | Goldman | Buy |
2022-02-10 | 개시 | SVB Leerink | Outperform |
2022-01-06 | 개시 | Cowen | Outperform |
2021-11-09 | 개시 | Canaccord Genuity | Buy |
2021-11-08 | 개시 | Morgan Stanley | Overweight |
2021-11-08 | 개시 | Wedbush | Outperform |
모두보기
2seventy bio Inc 주식(TSVT)의 최신 뉴스
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
Zacks Investment Research
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Zacks Investment Research
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Zacks Investment Research
2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks Investment Research
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
Zacks Investment Research
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
Zacks Investment Research
2seventy bio Inc (TSVT) 재무 분석
2seventy bio Inc (TSVT) 매출 2024
TSVT은 2023-12-31 종료 분기에 대해 매출(지난 12개월)이 100.39M 달러로 보고했으며, 전년대비 +9.72% 상승했습니다.
2seventy bio Inc (TSVT) 순이익 2024
TSVT은 2023-12-31 종료 분기에 대해 순이익(지난 12개월)이 -217.57M 달러로 보고했으며, 전년대비 +14.39% 증가했습니다.
2seventy bio Inc (TSVT) 현금흐름 2024
2023-12-31 종료 분기에 TSVT은 현금흐름(지난 12개월)으로 -180.72M 달러를 기록했으며, 전년 대비 +30.21% 증가했습니다.
2seventy bio Inc (TSVT) 주당 순이익 2024
TSVT이 보고한 2023-12-31 종료 분기의 주당 순이익(지난 12개월)은 -4.42달러이며, 전년 대비 +40.59% 성장했습니다.
2seventy bio Inc 주식 (TSVT) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Casdin Capital, LLC | Director |
Mar 25 '24 |
Buy |
5.07 |
330,000 |
1,673,991 |
1,960,000 |
Casdin Capital, LLC | Director |
Mar 22 '24 |
Buy |
5.12 |
147,377 |
754,069 |
1,630,000 |
Casdin Capital, LLC | Director |
Mar 21 '24 |
Buy |
4.90 |
300,000 |
1,470,990 |
1,482,623 |
Leschly Nick | President and CEO |
Jan 05 '24 |
Sale |
3.75 |
1,554 |
5,833 |
1,085,476 |
Baird William D III | Chief Operating Officer |
Jan 05 '24 |
Sale |
3.75 |
1,380 |
5,180 |
161,335 |
Gregory Philip D | Chief Scientific Officer |
Jan 05 '24 |
Sale |
3.75 |
795 |
2,984 |
230,842 |
Leschly Nick | President and CEO |
Jan 03 '24 |
Sale |
3.87 |
72,312 |
279,739 |
1,087,030 |
Baird William D III | Chief Operating Officer |
Jan 03 '24 |
Sale |
3.87 |
33,651 |
130,179 |
162,715 |
Gregory Philip D | Chief Scientific Officer |
Jan 03 '24 |
Sale |
3.87 |
25,613 |
99,084 |
231,637 |
Leschly Nick | President and CEO |
Aug 22 '23 |
Sale |
5.49 |
9,312 |
51,090 |
1,159,342 |
자본화:
|
볼륨(24시간):